FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-31

Price

$14.46

+0.21%

Score6.5Priority

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 6

Volume0.8xvs 20d avg

Analysis

FOLD is exhibiting the hallmark technical signatures of a late-stage merger arbitrage play, trading with ultra-low 1.9% annualized volatility as it touches 52-week highs. Recent news confirms that shareholders have officially approved the company's acquisition by BioMarin Pharmaceutical, shifting the market's focus entirely to deal closure. The ALPHA_MALE and QUIET_STORM signals perfectly capture this deal-price convergence, as institutional arbitrageurs pin the stock near Jefferies' revised $14.50 price target. In the current CAUTION macro regime, this M&A situation provides a low-beta safe haven, explaining FOLD's impressive +5.5% relative strength against a broader bearish market tide.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKINSIDE OUT

Key Takeaways

Actionable Thesis: FOLD is functioning as a pure merger arbitrage vehicle, with price action pinned tightly near the $14.50 level following shareholder approval of the BioMarin buyout.
Key Risk: The primary downside risk is deal collapse or renegotiation stemming from unresolved litigation issues highlighted in recent proxy documents, which recently prompted a Jefferies downgrade.
What to Watch: Monitor the $14.33 line-in-the-sand; a high-volume break below this floor would indicate institutional arb desks are unwinding their positions due to legal or regulatory pessimism.

← Back to 2026-03-31 View Full FOLD History →Yahoo Finance &nearr;